Posted by Michael Wonder on 14 Nov 2017
Institute for Clinical and Economic Review releases draft evidence report on voretigene neparvovec, gene therapy for blindness
14 November 2017 - Public comment period now open until 13 December; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Spark Therapeutics), a potentially one-time gene therapy for vision loss due to biallelic RPE65-mediated inherited retinal disease. The report, along with draft voting questions, will be open to public comment for four weeks.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Prior to conducting this review, ICER spoke with key patient groups and clinical experts, and accepted public comments on a Draft Scoping Document. The current draft report incorporates input received from patients, clinicians, and other stakeholders during each of these opportunities for engagement.
